 MUNICH, GERMANY ACCESSWIRE May 20, 2020 MorphoSys AG MOR.F Prime Standard Segment; MDAX TecDAX; MOR and Incyte INCY today announced the validation of the European Marketing Authorization Application MAA for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma rr DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation ASCT. 